title: Separate and combined effects of gabapentin and [INCREMENT]9-tetrahydrocannabinol in humans discriminating [INCREMENT]9-tetrahydrocannabinol.
abstract: The aim of the present study was to examine a potential mechanism of action of gabapentin to manage cannabis-use disorders by determining the interoceptive effects of gabapentin in cannabis users discriminating [INCREMENT]-tetrahydrocannabinol ([INCREMENT]-THC) using a pharmacologically selective drug-discrimination procedure. Eight cannabis users learned to discriminate 30 mg oral [INCREMENT]-THC from placebo and then received gabapentin (600 and 1200 mg), [INCREMENT]-THC (5, 15, and 30 mg), and placebo alone and in combination. Self-report, task performance, and physiological measures were also collected. [INCREMENT]-THC served as a discriminative stimulus, produced positive subjective effects, elevated heart rate, and impaired psychomotor performance. Both doses of gabapentin substituted for the [INCREMENT]-THC discriminative stimulus and engendered subjective and performance-impairing effects that overlapped with those of [INCREMENT]-THC when administered alone. When administered concurrently, gabapentin shifted the discriminative-stimulus effects of [INCREMENT]-THC leftward/upward, and combinations of [INCREMENT]-THC and gabapentin generally produced larger effects on cannabinoid-sensitive outcomes relative to [INCREMENT]-THC alone. These results suggest that one mechanism by which gabapentin might facilitate cannabis abstinence is by producing effects that overlap with those of cannabinoids.
authors: Departments of aBehavioral SciencebPsychiatrycInternal Medicine, College of MedicinedDepartment of Psychology, College of Arts and Sciences, University of Kentucky, Lexington, Kentucky, USA.
authors: Joshua A
authors: JA
authors: Lile
authors: Michael J
authors: MJ
authors: Wesley
authors: Thomas H
authors: TH
authors: Kelly
authors: Lon R
authors: LR
authors: Hays
mesh_terms: D000588:Amines / Q000627:therapeutic use*; D000704:Analysis of Variance; D001794:Blood Pressure / Q000187:drug effects; D001831:Body Temperature / Q000187:drug effects; D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use*; D004193:Discrimination Learning / Q000187:drug effects*; D013759:Dronabinol / Q000627:therapeutic use*; D004338:Drug Combinations; D018691:Excitatory Amino Acid Antagonists / Q000627:therapeutic use*; D005260:Female; D000077206:Gabapentin; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D002189:Marijuana Abuse / Q000188:drug therapy*; D017063:Outcome Assessment, Health Care; D011597:Psychomotor Performance / Q000187:drug effects; D011795:Surveys and Questionnaires; D064232:Visual Analog Scale; D005680:gamma-Aminobutyric Acid / Q000627:therapeutic use*
chemical_list: D000588:Amines; D003509:Cyclohexanecarboxylic Acids; D004338:Drug Combinations; D018691:Excitatory Amino Acid Antagonists; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin; D013759:Dronabinol